在肥胖成人中,一种新的口服西磁酸盐药丸导致体重大幅下降,63%的体重至少丧失10%。 A new oral semaglutide pill caused significant weight loss in obese adults, with 63% losing at least 10% of body weight.

一项新的临床试验发现,在Ozempic和Wegovy, 一种每日口服含有甘油的口服避孕药,作为Ozempic和Wegovy的活性成分,导致超重或肥胖成年人体重大幅下降,参加者平均在64周内损失近14%的体重,而安慰剂组则减少了2%。 A new clinical trial found that a daily oral pill containing semaglutide, the active ingredient in Ozempic and Wegovy, led to significant weight loss in overweight or obese adults, with participants losing nearly 14% of their body weight on average over 64 weeks—compared to 2% in the placebo group. 约有63%的避孕药使用者体重至少损失10%,近30%的避孕药使用者损失20%或以上,有些人在严格遵守避孕药疗法的人中损失高达17%。 About 63% of pill users lost at least 10% of their body weight, and nearly 30% lost 20% or more, with some achieving up to 17% loss among those who adhered closely to the regimen. 副作用大多是胃肠效应,与注射形式相似,尽管其出现较晚,持续时间更长。 Side effects were mostly gastrointestinal and similar to injectable forms, though they appeared later and lasted longer. 这些结果公布在《新英格兰医学杂志》上,连同另一口服GLP-1药物或forgliprion的有希望的数据。 The results, published in the New England Journal of Medicine, come alongside promising data for another oral GLP-1 drug, orforgliprion. 专家说,口头版本可以改善获得和遵守情况,特别是考虑到目前只有不到2%的肥胖症美国成年人使用药物。 Experts say oral versions could improve access and adherence, especially given that fewer than 2% of U.S. adults with obesity currently use medication. 资助该试验的诺沃诺迪斯克公司计划寻求FDA批准,如果获得批准,将满足美国预期的需求. Novo Nordisk, which funded the trial, plans to seek FDA approval and meet expected U.S. demand if approved.